IRVINE, Calif., and HERNDON, Va., Dec. 15 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (BULLETIN BOARD: CLBE) , which is focused on acquiring, incubating and developing early stage life science companies and technologies, today announced that Molecula ( http://www.molecula.com/ ), Herndon, Virginia, a subsidiary of CalbaTech, received a non-exclusive license to Patent 6,506,599, "Genetic Inhibition by Double-Stranded RNA," from the Carnegie Institution of Washington.
Matt Maupin, Molecula CEO, stated that "Molecula is one of the leading companies in gene silencing technologies for gene and protein function studies. This is the most important patent in RNAi technology, and this license allows Molecula to aggressively compete in the RNAi market, which is expanding at an enormous rate. This is the most widely licensed patent relating to RNAi technology and allows Molecula to complete important distribution and partnership agreements that have been pending for some time."
Molecula's technology permits delivery of active siRNA or antisense to target genes with a high rate of success. Molecula has particular expertise in design technology and has been in the gene silencing business for ten years with its antisense design technology.
Molecula plans on offering a comprehensive RNAi portfolio, and is in discussions with major international partners to provide its RNAi products worldwide. Molecula also sells transfection reagents, The Inducer(TM) -- a novel IPTG replacement for increased protein expression, neuropeptides and biochemicals.
The Carnegie Institution ( http://www.carnegieinstitution.org/ ), Washington, D.C., has been a pioneering force in basic scientific research since 1902. It is a private, nonprofit organization with six research departments in the U.S.: Embryology, Geophysical Laboratory, Terrestrial Magnetism, The Observatories, Plant Biology, and Global Ecology.
CalbaTech, Inc. (BULLETIN BOARD: CLBE) is an emerging life sciences company that is concentrating on providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. CalbaTech is focused on acquiring, incubating and developing early stage life science companies and next generation products and technologies, both in the United States and the United Kingdom. In addition to growth through acquisition, CalbaTech is focused on breakthrough innovation in areas of biological discovery. More information is available at http://www.calbatech.com/ .
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.